Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries
Marcello Arca, Simone Celant, Pier Paolo Olimpieri, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 21
Open Access | Times Cited: 16

Showing 16 citing articles:

Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study
Kausik K. Ray, Carlos Aguíar, Marcello Arca, et al.
European Journal of Preventive Cardiology (2024) Vol. 31, Iss. 15, pp. 1792-1803
Open Access | Times Cited: 10
Quo Vadis after AEGIS: New Opportunities for Therapies Targeted at Reverse Cholesterol Transport?
N. Lan, Gerald F. Watts
Current Atherosclerosis Reports (2025) Vol. 27, Iss. 1
Open Access
Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study
Nitin B. Charbe, Flavia C. Zacconi, Venkata Krishna Kowthavarapu, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 286-286
Open Access | Times Cited: 2
Flexible Approaches Based on Multistate Models and Microsimulation to Perform Real-World Cost-Effectiveness Analyses: An Application to Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors
Caterina Gregorio, Federico Rea, Francesca Ieva, et al.
Value in Health (2024) Vol. 27, Iss. 7, pp. 897-906
Open Access | Times Cited: 2
Monoclonal Anti-PCSK9 Antibodies: Real-World Data
Giulia Guidotti, Viola Liberati, A. Sorrentino, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 15, pp. 4543-4543
Open Access | Times Cited: 2
Surgical Treatment of Multiple Large Tuberous and Tendinous Xanthoma Secondary to Familial Hypercholesterolaemia: A Case Report
Haonan Guan, Guoyou Zhang, Qiqi Li, et al.
Clinical Cosmetic and Investigational Dermatology (2024) Vol. Volume 17, pp. 961-966
Open Access | Times Cited: 1
Exploring the Potential and Challenges of CRISPR Delivery and Therapeutics for Genetic Disease Treatment
Xinpu Yang, Thuỳ Anh Bùi, Haoqi Mei, et al.
Advanced Functional Materials (2024) Vol. 34, Iss. 38
Closed Access | Times Cited: 1
A therapeutic cooperation by bempedoic acid and proprotein convertase subtilisin/kexin type 9 inhibitors in statin intolerance inherited dyslipidemias
Francesco Sbrana, Federico Bigazzi, Carmen Corciulo, et al.
Internal and Emergency Medicine (2024)
Closed Access | Times Cited: 1
Emerging Biomarkers and Determinants of Lipoprotein Profiles to Predict CVD Risk: Implications for Precision Nutrition
Catherine J. Andersen, María Luz Fernández
Nutrients (2024) Vol. 17, Iss. 1, pp. 42-42
Open Access | Times Cited: 1
Place des inhibiteurs du PCSK9 dans le traitement des hypercholestérolémies
Cécile Yelnik
La Presse Médicale Formation (2024) Vol. 5, Iss. 2, pp. 145-150
Open Access
Recurrent Acute Coronary Syndrome in Young Man with Familial Hypercholesterolemia: Efficacy of Evolocumab Add-On Treatment Demonstrated via Serial Coronary Angiography
Narae Kim, Jin‐Man Cho, In‐Ho Yang
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1113-1113
Open Access
Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records
Giulia Barbati, Caterina Gregorio, Arjuna Scagnetto, et al.
PLoS ONE (2024) Vol. 19, Iss. 8, pp. e0309470-e0309470
Open Access
Real‐world effectiveness of monoclonal antibody inhibitors of PCSK9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study
Rebecca Siemens, Mark Pryjma, Susan Buchkowsky, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 9, pp. 730-737
Open Access
New Epigenome Players in the Regulation of PCSK9 – H3K4me3 and H3K9ac Alteration by Statins in hypercholesterolemia
Sushmitha Duddu, Yash T. Katakia, Rituparna Chakrabarti, et al.
Journal of Lipid Research (2024), pp. 100699-100699
Open Access
Pediatrics cascade screening in inherited dyslipidemias: a lipoprotein apheresis center experience
Francesco Sbrana, Beatrice Dal Pino, Carmen Corciulo, et al.
Endocrine (2024)
Closed Access
Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome
Željka Dragila, Matea Lozert, Silvija Canecki-Varžić, et al.
Medicinski Glasnik (2023) Vol. 21, Iss. 1, pp. 29-35
Open Access
Page 1

Scroll to top